Insperity (NSP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
14 Apr, 2026Executive summary
Annual Meeting scheduled for May 18, 2026, with four key proposals for shareholder action, including director elections, executive compensation, incentive plan amendment, and auditor ratification.
Shareholders of record as of April 6, 2026, are eligible to vote; multiple voting methods are available.
The company continues to invest in a new HRScale solution with Workday, aiming for long-term growth despite recent declines in adjusted EBITDA.
Regular annual dividends were maintained at $2.40 per share in 2025, a record for the company.
Voting matters and shareholder proposals
Proposal 1: Election of four Class I directors for terms expiring in 2029.
Proposal 2: Advisory vote to approve executive compensation (say-on-pay).
Proposal 3: Approval of the Second Amendment to the Incentive Plan, increasing shares reserved for issuance by 1,620,000.
Proposal 4: Ratification of Ernst & Young LLP as independent auditor for 2026.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of 11 members, with a mix of industry, financial, and leadership experience; three female directors and two from underrepresented groups.
All directors except the CEO and a retired executive are considered independent.
Committees: Finance, Risk Management & Audit; Compensation; Nominating & Corporate Governance; and a Commonality, Equality & Cohesion Board Liaison.
Lead independent director role established; executive sessions held regularly.
Stockholder engagement and communication channels are in place.
Latest events from Insperity
- Solid Q4 results, resilient profitability, and Workday partnership set stage for 2025 growth.NSP
Q4 20249 Jul 2026 - Q2 2024 saw robust profit growth, but 2024 guidance was cut amid SMB market headwinds.NSP
Q2 20248 Jul 2026 - Margin recovery and cost controls offset lower worksite employee growth and pressured profits.NSP
Q1 20268 Jul 2026 - 2026 guidance targets margin recovery and growth, led by HRScale and cost controls.NSP
Q4 202513 Feb 2026 - Q3 net income and EPS dropped sharply, with full-year adjusted EPS guided at $3.42–$3.66.NSP
Q3 202417 Jan 2026 - Higher healthcare costs and economic uncertainty drove lower Q1 earnings despite revenue growth.NSP
Q1 202524 Dec 2025 - Annual Meeting to vote on directors, pay, incentive plan amendment, and auditor ratification.NSP
Proxy Filing1 Dec 2025 - Q3 revenue up 4% but net loss and EBITDA fell on higher costs; 2026 recovery expected.NSP
Q3 202513 Nov 2025 - Higher benefits costs drove Q2 profit declines, but 2026 profitability outlook remains strong.NSP
Q2 202531 Oct 2025